Results 1 to 10 of about 26,125 (257)
Design and Production of Bispecific Antibodies [PDF]
Antibodies, 2019 With the current biotherapeutic market dominated by antibody molecules, bispecific antibodies represent a key component of the next-generation of antibody therapy.
Qiong Wang, Yiqun Chen, Jaeyoung Park
exaly +5 more sources
Bispecific antibodies in cancer immunotherapy
Therapeutic Advances in Vaccines and Immunotherapy, 2018 Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and ...
Niina Veitonmaki
exaly +2 more sources
Development of Bispecific Antibody Targeting Human IL-17A and IL-6 [PDF]
AntibodiesBackground/Objectives: Antibodies are a rapidly expanding field in drug discovery, but their monospecificity limits therapeutic applications, particularly in complex inflammatory diseases.
Beata Pamuła +13 more
doaj +2 more sources
Bispecific antibodies for viral immunotherapy [PDF]
Human Vaccines & Immunotherapeutics, 2017 Bispecific antibody engineering, in which binding specificities toward 2 distinct epitopes are combined into a single molecule, can greatly enhance immunotherapeutic properties of monoclonal antibodies.
Elisabeth K. Nyakatura +2 more
doaj +3 more sources
Bispecific antibodies in follicular lymphoma
HaematologicaBispecific antibodies, specifically anti-CD20 T-cell engaging constructs, are poised to alter the treatment paradigm of multiple B-cell malignancies, including follicular lymphoma.
Imran A. Nizamuddin, Nancy L. Bartlett
doaj +3 more sources
Production of native bispecific antibodies in rabbits. [PDF]
PLoS ONE, 2010 BACKGROUND: A natural bispecific antibody, which can be produced by exchanging Fab arms of two IgG4 molecules, was first described in allergic patients receiving therapeutic injections with two distinct allergens.
Wei Wang, Ruihuan Xu, Jinming Li
doaj +1 more source
Hematology, 2023 Abstract Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
de Assis, Luiz Henrique +2 more
openaire +3 more sources
Identification of natural bispecific antibodies against cyclic citrullinated peptide and immunoglobulin G in rheumatoid arthritis. [PDF]
PLoS ONE, 2011 BACKGROUND: Previous studies indicate that natural bispecific antibodies can be readily produced in vivo when the body is simultaneously stimulated with 2 distinct antigens.
Wei Wang, Jinming Li
doaj +1 more source
mAbs, 2021 Bispecific antibodies have recently attracted intense interest. CrossMab technology was described in 2011 as novel approach enabling correct antibody light-chain association with their respective heavy chain in bispecific antibodies, together with ...
Marlena Surowka +2 more
doaj +1 more source
Bispecific antibodies and their applications [PDF]
Journal of Hematology & Oncology, 2015 Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites.
Fan, Gaowei +3 more
openaire +2 more sources